MX363746B - Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal. - Google Patents
Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.Info
- Publication number
- MX363746B MX363746B MX2015013255A MX2015013255A MX363746B MX 363746 B MX363746 B MX 363746B MX 2015013255 A MX2015013255 A MX 2015013255A MX 2015013255 A MX2015013255 A MX 2015013255A MX 363746 B MX363746 B MX 363746B
- Authority
- MX
- Mexico
- Prior art keywords
- colorectal cancer
- methods
- treating
- treating colorectal
- smad7
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title abstract 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 101700026522 SMAD7 Proteins 0.000 abstract 3
- 102000049873 Smad7 Human genes 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un oligonucleótido antisentido de SMAD7 para usarse en el tratamiento de cáncer colorrectal en un paciente, en donde el oligonucleótido antisentido de SMAD7 comprende una secuencia de nucleótidos de SEQ ID NO: 6, o SEQ ID NO: 10.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361790488P | 2013-03-15 | 2013-03-15 | |
US201361847287P | 2013-07-17 | 2013-07-17 | |
PCT/EP2014/055195 WO2014140333A1 (en) | 2013-03-15 | 2014-03-14 | Methods of treating colorectal cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015013255A MX2015013255A (es) | 2015-12-15 |
MX363746B true MX363746B (es) | 2019-04-01 |
Family
ID=50390057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013255A MX363746B (es) | 2013-03-15 | 2014-03-14 | Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2970419B8 (es) |
JP (2) | JP6502863B2 (es) |
KR (1) | KR102232623B1 (es) |
CN (1) | CN105008394B (es) |
AU (1) | AU2014229985B2 (es) |
CA (1) | CA2903597C (es) |
ES (1) | ES2673209T3 (es) |
HK (1) | HK1219489A1 (es) |
MX (1) | MX363746B (es) |
NZ (1) | NZ711564A (es) |
RU (1) | RU2674147C2 (es) |
WO (1) | WO2014140333A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
PT2364360T (pt) | 2008-11-13 | 2017-06-27 | Nogra Pharma Ltd | Composições em sentido reverso e métodos de as fabricar e utilizar |
EP2748611B1 (en) | 2011-09-15 | 2016-11-23 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
NZ630914A (en) | 2012-04-18 | 2017-01-27 | Nogra Pharma Ltd | Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation |
US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
WO2015169966A2 (en) | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
EA201790867A1 (ru) | 2014-10-17 | 2017-08-31 | Ногра Фарма Лимитед | Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7 |
US20180289692A1 (en) * | 2015-09-30 | 2018-10-11 | Celgene Corporation | Tlr modulators and methods of use |
WO2017147276A1 (en) | 2016-02-23 | 2017-08-31 | Celgene Corporation | Methods of treating intestinal fibrosis using smad7 inhibition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
US7402574B2 (en) * | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
US20080114287A1 (en) * | 2006-11-14 | 2008-05-15 | Kar Neng Lai | Ultrasound Microbubble Mediated Genes Delivery System |
PT2364360T (pt) * | 2008-11-13 | 2017-06-27 | Nogra Pharma Ltd | Composições em sentido reverso e métodos de as fabricar e utilizar |
UA107562C2 (uk) * | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
EP2748611B1 (en) * | 2011-09-15 | 2016-11-23 | Nogra Pharma Limited | Methods for monitoring responsiveness to anti-smad7 therapy |
-
2014
- 2014-03-14 EP EP14713401.9A patent/EP2970419B8/en active Active
- 2014-03-14 MX MX2015013255A patent/MX363746B/es active IP Right Grant
- 2014-03-14 AU AU2014229985A patent/AU2014229985B2/en active Active
- 2014-03-14 CN CN201480016188.7A patent/CN105008394B/zh active Active
- 2014-03-14 RU RU2015140572A patent/RU2674147C2/ru active
- 2014-03-14 WO PCT/EP2014/055195 patent/WO2014140333A1/en active Application Filing
- 2014-03-14 KR KR1020157029231A patent/KR102232623B1/ko active IP Right Grant
- 2014-03-14 JP JP2015562243A patent/JP6502863B2/ja active Active
- 2014-03-14 NZ NZ711564A patent/NZ711564A/en unknown
- 2014-03-14 CA CA2903597A patent/CA2903597C/en active Active
- 2014-03-14 ES ES14713401.9T patent/ES2673209T3/es active Active
-
2016
- 2016-06-27 HK HK16107450.0A patent/HK1219489A1/zh unknown
-
2018
- 2018-10-23 JP JP2018199148A patent/JP2019026649A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
RU2015140572A (ru) | 2017-04-24 |
ES2673209T8 (es) | 2020-02-12 |
JP6502863B2 (ja) | 2019-04-17 |
CA2903597C (en) | 2023-04-04 |
EP2970419B8 (en) | 2019-12-11 |
EP2970419A1 (en) | 2016-01-20 |
JP2019026649A (ja) | 2019-02-21 |
HK1219489A1 (zh) | 2017-04-07 |
RU2674147C2 (ru) | 2018-12-05 |
MX2015013255A (es) | 2015-12-15 |
WO2014140333A1 (en) | 2014-09-18 |
KR20150131260A (ko) | 2015-11-24 |
KR102232623B1 (ko) | 2021-03-26 |
AU2014229985B2 (en) | 2018-12-13 |
AU2014229985A1 (en) | 2015-09-10 |
CN105008394A (zh) | 2015-10-28 |
CN105008394B (zh) | 2021-10-22 |
NZ711564A (en) | 2020-04-24 |
RU2015140572A3 (es) | 2018-03-21 |
EP2970419B1 (en) | 2018-05-09 |
CA2903597A1 (en) | 2014-09-18 |
JP2016517401A (ja) | 2016-06-16 |
ES2673209T3 (es) | 2018-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502810A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
NZ711564A (en) | Methods of treating colorectal cancer | |
PH12019501197A1 (en) | Therapeutically active compounds and their methods of use | |
PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
MX371108B (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
PH12016501790B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
HK1217289A1 (zh) | 使用細菌治療癌症的組合物和方法 | |
EP2943565A4 (en) | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF IMMUNE CELLS FOR TREATING TUMOR CELLS THAT ARE NOT RESTRICTED OR UNREQUIRED AND A TUMOR RECIPIENT | |
EP3065772A4 (en) | Combinations of checkpoint inhibitors and therapeutics to treat cancer | |
MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
PH12016501788B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
SG194469A1 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
MX2017006015A (es) | Composiciones para usar en el tratamiento de cancer renal. | |
MX2015013021A (es) | 5-bromo-indirrubinas. | |
EP3010504A4 (en) | Methods and compositions to treat cancer | |
MY182434A (en) | Certain chemical entities, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |